The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma Journal Articles

abstract

• AbstractThe term limited-stage Hodgkin lymphoma refers to those patients with stage I–II disease and an absence of bulky disease. Among those patients with classical Hodgkin lymphoma, approximately one-third of patients will fall into this category. As long-term disease control can now be anticipated in more than 90% of these patients, management strategies must increasingly address the need to reduce the long-term treatment-related risks. Current treatment options include use of combined modality therapy that includes an abbreviated course of chemotherapy and involved-field radiation or treatment with chemotherapy, currently consisting of ABVD, as a single modality. The choice of treatment between these two options involves specific trade-offs that must balance issues of disease control against long-term risk of late effects.

authors

• Gospodarowicz, Mary K
• Meyer, Ralph

status

• published 

publication date

• January 1, 2006

has subject area

• Combined Modality Therapy (MeSH)
• Disease Management (MeSH)
• Hodgkin Disease (MeSH)
• Humans (MeSH)
• Neoplasm Staging (MeSH)
• Risk Assessment (MeSH)

published in

• Hematology. American Society of Hematology. Education Program  Journal

keywords

• Combined Modality Therapy
• Disease Management
• Hodgkin Disease
• Humans
• Neoplasm Staging
• Risk Assessment

Digital Object Identifier (DOI)

• 10.1182/asheducation-2006.1.253

PubMed ID

• 17124069

start page

• 253

end page

• 258

volume

• 2006

issue

• 1